Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Gentex Corporation (GNTX) Steven Downing on Q2 2018 Results - Earnings Call Transcript

16m seekingalpha
Good day, ladies and gentlemen, and welcome to the Gentex Second Quarter 2018 Earnings Call. At this time, all participants are in a listen-only mode. [Operator Instructions] Later, we will conduct a question-and-answer session and instructions will follow at that time.
GNTX

15
Factbox: Impact of U.S-China trade tariffs on U.S. companies

4h reuters
(Reuters) - Several U.S. companies are putting in place measures to cushion the impact of escalating trade tensions between the United States and China.
GEC GE GNTX GNE DHR HOME

0
Gentex (GNTX) Misses Q2 Earnings and Revenue Estimates

6h zacks
Gentex (GNTX - Free Report) just came out with quarterly earnings of $0.40 per share, missing the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.31 per share a year ago. These figures are adjusted for non-recurring items.
CFIN RF.PRB RF.PRA GNTX KDP CIWV RF

0
Gentex Reports Second Quarter 2018 Financial Results

8h globenewswire
ZEELAND, Mich., July 20, 2018 (GLOBE NEWSWIRE) -- Gentex Corporation (NASDAQ:GNTX) the Zeeland, Michigan-based manufacturer of automotive automatic-dimming rearview mirrors, automotive electronics, dimmable aircraft windows, and fire protection products, today reported financial results for the three and six months ended June 30, 2018.
GNTX

0
GNTX / Gentex Corp. 8-K (Current Report)

8h sec.gov
Document UNITED STATES
GNTX

7
My Best Ideas For Auto And Truck Part Manufacturers

2018-06-11 seekingalpha
With all the talk about Auto 2.0 and autonomous cars, it seems to be the time to latch onto the changes that the auto parts industry will face in the coming years. The industry is clearly in transition and now may be a good time to invest in the best the industry has to offer.
DORM LEA GNTX MGA MG

1
GNTX / Gentex Corp. SD

2018-05-30 sec.gov
Document UNITED STATES
GNTX

1
GNTX / Gentex Corp. 8-K (Current Report)

2018-05-27 sec.gov
Document UNITED STATES
GNTX

189
My Favorite Dividend Growth Stocks

2018-05-27 seekingalpha
Throughout the years, I've studied, researched and tried many different investing styles. Since 2010, I've become a dividend growth investor, but not the classic buy & hold guy. I divide my portfolio into two distinct sections: a core portfolio and a growth portion.
BLK GNTX AAPL

59
AutoZone's (AZO) Q3 Earnings Beat Estimates, Revenues Miss

2018-05-22 zacks
AutoZone, Inc. (AZO - Free Report) reported earnings of $13.42 per share in the third quarter of fiscal 2018 (ended May 5, 2018), beating the Zacks Consensus Estimate of $12.99. The figure was $11.44 in third-quarter fiscal 2017. Revenues improved 1.6% year over year to $2.66 billion in the reported quarter. However, the figure missed the Zacks Consensus Estimate of $2.71 billion. Domestic same-store sales (sales of stores open at least for a year) rose 0.
HAFC GNTX OSK AZO AAP AKAM

1
GNTX / Gentex Corp. 8-K (Current Report)

2018-05-21 sec.gov
Document UNITED STATES
GNTX

3
Superior Industries Rides On Volumes & UNIWHEELS Buyout

2018-05-17 zacks
On May 16, we issued an updated research report on Superior Industries International, Inc. (SUP - Free Report) . The company reported first-quarter 2018 results on May 9. The company reported adjusted earnings of 15 cents per share, beating the Zacks Consensus Estimate of 4 cents. Also, revenues were $386.4 million in the reported quarter, beating the Zacks Consensus Estimate of $356.2 million. Moreover, the top line was higher than the year-ago quarter figure.
GNTX OSK SUP

1
Tesla to Halt Production Line to Address Model 3 Bottlenecks

2018-05-16 zacks
Per Reuters, Tesla, Inc. (TSLA - Free Report) will halt production for six days at its general assembly in Fremont, CA factory between May 26 and May 31. Earlier, this electric-vehicle frontrunner struggled to ramp up the production of its new high-impact Model 3 sedan to the levels promised by the company. The proposed six-day shutdown at the end of May is aimed at to address production bottlenecks and work on its assembly line.
GNTX OSK

7
Westport Fuel Systems (WPRT) Gains From HPDI 2.0 Product

2018-05-15 zacks
On May 14, we issued an updated research report on Westport Fuel Systems Inc. (WPRT - Free Report) . The company reported first-quarter 2018 results on May 10. Westport Fuel Systems reported adjusted net loss from continuing operations of 10 cents per share, narrower than the Zacks Consensus Estimate of a loss of 11 cents. Net loss in the prior-year quarter was 12 cents per share. During the reported quarter, Westport Fuel Systems recorded consolidated revenues of $67.
GD GNTX OSK CSX

7
Honda to Invest $30M in Ohio Facilities to Boost Production

2018-05-15 zacks
Honda Motor Co., Ltd. (HMC - Free Report) reportedly made the announcement of investing over $30 million at its three facilities in Ohio. This investment is in sync with the company’s strategy to ramp up the production of its electric vehicles. Notably, this Japanese auto giant just began the production of its new 2019 Honda Insight hybrid model at its Greensburg, IN facility. In sync with that strategy, the company announced to invest $29 million at the Honda Transmission Manufacturing of America plant in Logan County’s Russells Point.
GD GNTX OSK CSX

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to GNTX / Gentex Corp. on message board site Silicon Investor.

Gentex (GNTX)
CUSIP: 371901109